Cannata-Andía Jorge B, Carrillo-López Natalia, Messina Osvaldo D, Hamdy Neveen A T, Panizo Sara, Ferrari Serge L
Bone and Mineral Research Unit, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Retic REDinREN-ISCIII, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain.
Investigaciones Reumatológicas y Osteológicas (IRO), Buenos Aires 1114, Argentina.
Nutrients. 2021 Oct 27;13(11):3835. doi: 10.3390/nu13113835.
Vascular Calcification (VC), low bone mass and fragility fractures are frequently observed in ageing subjects. Although this clinical observation could be the mere coincidence of frequent age-dependent disorders, clinical and experimental data suggest that VC and bone loss could share pathophysiological mechanisms. Indeed, VC is an active process of calcium and phosphate precipitation that involves the transition of the vascular smooth muscle cells (VSMCs) into osteoblast-like cells. Among the molecules involved in this process, parathyroid hormone (PTH) plays a key role acting through several mechanisms which includes the regulation of the RANK/RANKL/OPG system and the Wnt/ß-catenin pathway, the main pathways for bone resorption and bone formation, respectively. Furthermore, some microRNAs have been implicated as common regulators of bone metabolism, VC, left ventricle hypertrophy and myocardial fibrosis. Elucidating the common mechanisms between ageing; VC and bone loss could help to better understand the potential effects of osteoporosis drugs on the CV system.
血管钙化(VC)、低骨量和脆性骨折在老年人群中很常见。尽管这种临床观察可能只是常见的年龄依赖性疾病的巧合,但临床和实验数据表明,VC和骨质流失可能共享病理生理机制。事实上,VC是钙和磷酸盐沉淀的一个活跃过程,涉及血管平滑肌细胞(VSMC)向成骨细胞样细胞的转变。在参与这一过程的分子中,甲状旁腺激素(PTH)通过多种机制发挥关键作用,其中包括调节RANK/RANKL/OPG系统和Wnt/β-连环蛋白途径,这两条途径分别是骨吸收和骨形成的主要途径。此外,一些微小RNA被认为是骨代谢、VC、左心室肥厚和心肌纤维化的共同调节因子。阐明衰老、VC和骨质流失之间的共同机制有助于更好地理解骨质疏松药物对心血管系统的潜在影响。